Galderma, an independent dermatology company, announces thatย it has received antitrust clearance fromย the USย authoritiesย andย has completed the acquisitionย ofย ALASTIN Skincare Inc, a specialty aesthetics company that develops physician-dispensed skincare products.ย Theย transaction was previously announced onย November 29, 2021.ย
โI am so happy to officially welcome the ALASTIN team to Galderma. As a part of our integrated dermatology approach, we are continuously seeking to add products that synergize with our premium portfolio – and ALASTIN is the perfect fit.
The ALASTIN brandโs proprietary and award-winning skincare technology, combined with Galdermaโs world-class pipeline and innovation track record, represents an unparalleled opportunity for Galderma to better meet the needs of aesthetic professionals and patients, now and well into the future.โ
— Flemming รrnskov, MD, MPH, Chief Executive Officer, Galderma
ALASTIN’s product offerings are backed by the patented TriHex Technology, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. Thisย acquisition will enhance Galdermaโs integrated dermatology platform with a comprehensive collectionย of scientifically proven products for daily skincare regimens and peri-procedural use, and underscoresย the companyโsย commitment to be the partner of choice for aestheticย professionals.ย
โOur team is extremely excited to be joining the Galderma family, and our shared focus on customers and commitment to driving innovation means weโre a winning combination. Galdermaโs global reach and cutting-edge research and development platform will help deliver ALASTINโs next growth phase and support further innovation of ALASTINโs products.โ
— Diane S Goostree, President and CEO, ALASTIN Skincare
[Source: Galderma]